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Statistical design and analysis in trials of
proportionate interventions: a systematic
review
Jane Candlish1* , M. Dawn Teare1, Judith Cohen1,3 and Tracey Bywater2
Abstract
Background: In proportionate or adaptive interventions, the dose or intensity can be adjusted based on individual
need at predefined decision stages during the delivery of the intervention. The development of such interventions
may require an evaluation of the effectiveness of the individual stages in addition to the whole intervention. However,
evaluating individual stages of an intervention has various challenges, particularly the statistical design and analysis.
This review aimed to identify the use of trials of proportionate interventions and how they are being designed and
analysed in current practice.
Methods: We searched MEDLINE, Web of Science and PsycINFO for articles published between 2010 and 2015
inclusive. We considered trials of proportionate interventions in all fields of research. For each trial, its aims, design and
analysis were extracted. The data synthesis was conducted using summary statistics and a narrative format.
Results: Our review identified 44 proportionate intervention trials, comprising 28 trial results, 13 protocols and three
secondary analyses. These were mostly described as stepped care (n = 37) and mainly focussed on mental health
research (n = 30). The other studies were aimed at finding an optimal adaptive treatment strategy (n = 7) in a variety
of therapeutic areas. Further terminology used included adaptive intervention, staged intervention, sequentially
multiple assignment trial or a two-phase design. The median number of decision stages in the interventions was two
and only one study explicitly evaluated the effect of the individual stages.
Conclusions: Trials of proportionate staged interventions are being used predominantly within the mental health
field. However, few studies consider the different stages of the interventions, either at the design or the analysis phase,
and how they may interact with one another. There is a need for further guidance on the design, analyses and
reporting across trials of proportionate interventions.
Trial registration: Prospero, CRD42016033781. Registered on 2 February 2016.
Keywords: Systematic review, Complex intervention, Trial, Proportionate intervention, Stepped care, Adaptive
treatment strategy, Adaptive intervention, Sequential multiple assignment randomised trial, Proportionate
universalism
Background
Many health, educational and social interventions have
multiple components. For a proportionate intervention,
these complex multi-component interventions are deliv-
ered in a proportionate or adaptive manner, in which the
components of the intervention are delivered in response
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to an individual’s need over time. Other analogous terms
for a proportionate intervention include adaptive inter-
vention, dynamic treatment regime and stepped care.
Proportionate interventions are multi-stage and defined
by a series of decision rules. The key features are criti-
cal time points, tailoring variables and treatment options.
An example of an adaptive intervention was described by
Almirall et al. [1]. This intervention aimed to improve out-
comes for children with autism who had minimal verbal
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
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skills. The treatment was discrete teaching and was deliv-
ered at stage 1 as two sessions per week over 12 weeks.
At 12 weeks, the child was assessed for change in spon-
taneous communication utterances since baseline (the
tailoring variable). At the critical time point at 12 weeks,
if the spontaneous communication utterances increased
by at least 25%, then the discrete teaching treatment con-
tinued at two sessions per week for the next 12 weeks.
If the change was below this, then the discrete teaching
treatment increased to three sessions per week.
The proportionate approach is based on the notion that
individuals differ in their response to treatment. Individ-
uals who require a step-up, step-down or switch in inter-
vention receive it. For those who are responding to the
current intervention, there is no increase in burden, such
as side effects or invested time. Additionally, all interven-
tions incur costs and multi-component interventions can
be both costly and resource intensive. Providing treatment
appropriate to individual need should improve efficiency
by reducing the costs of unnecessary further treatments
whilst conserving resources for those in greatest need.
Proportionate interventions are in keeping with recom-
mendations from the Strategic Review of Health Inequal-
ities in England after the 2010 Marmot Review [2], which
stated that actions and interventions should be both uni-
versal and targeted to reflect the level of need or disadvan-
tage. This idea was termed ‘proportionate universalism’.
Recent advances include just-in-time adaptive interven-
tions, which deliver treatment sensitive to an individual’s
changing needs for support. With technology, treatment
can be based on measurements of rapidly changing fac-
tors. In health or behavioural change interventions, this
allows a treatment to be delivered when a person is (a)
vulnerable or open to positive changes and (b) receptive.
Nahum-Shani et al. [3] developed a conceptual framework
to help guide the development of just-in-time adaptive
interventions, which is likely to be used more commonly
in clinical trials in the near future.
Evaluating a proportionate intervention in a randomised
controlled trial presents fresh challenges for the statisti-
cal study design and analysis outside current guidelines
for complex intervention research [4, 5]. Teams develop-
ing such proportionate interventions may wish to opti-
mise the intervention and thus, may want to evaluate
the incremental effectiveness of the individual stages in
addition to the overall intervention. In general, trials
randomise individuals or clusters to a whole interven-
tion package to assess effectiveness. However, a propor-
tionate intervention creates a variable number of lev-
els of intervention and frequently multiple hierarchical
levels of clustering occur, each dependent upon out-
comes at the previous stage of intervention. Clustering
may be non-random and dependent on an intermediate
outcome.
This review aimed to identify trials of proportionate
interventions and how they are being designed and anal-
ysed in current practice. Research into proportionate and
adaptive interventions has previously been done in other
forms or with a slightly different focus to this review [3, 6].
Early work by Collins et al. [6] presents a conceptual
framework for adaptive interventions. They discuss key
design principles including choice of tailoring variables
and the derivation of good decision rules. A good deci-
sion rule is objective and comprehensive and it will ensure
intervention components are delivered to individuals at
the intended intensity. Nahum et al. [3] reviewed how
adaptive interventions use decision rules to link individ-
ual responses with intervention options and the repeated
use of these rules to adapt interventions over time in
response to the changing response of individuals. They
discuss how sequential multiple-assignment randomised
trials (SMARTs) can be used to construct adaptive inter-
ventions, using a case study of an adaptive intervention
for children with attention deficit hyperactivity disorder
(ADHD) to illustrate analysis methods for the SMART
design. They compare first- and second-stage interven-
tion options, and the interventions embedded within the
SMART design. Proportionate or adaptive interventions
are desirable due to the heterogeneous responses to treat-
ments. Some people may need only a low-intensity inter-
vention while others may need a higher intensity or an
alternative intervention. However, the design of adaptive
intervention strategies must be driven by the scientific
research question. Almirall et al. [1] present an infor-
mative review of the optimal design and evaluation of
adaptive interventions in education research.
The current review moves beyond the work that has
already been conducted. It systematically reviews the
methods used in studies of proportionate interventions. It
will be useful for those planning and analysing trials in this
area, since we present fields in which proportionate inter-
ventions are currently being utilised, the types of tailoring
variables and the decision rules used.
We conducted a systematic review of published tri-
als to present the types of proportionate interventions
being evaluated and the design and analysis methods
being undertaken in current practice. Without knowing
the variety of proportionate interventions and scenar-
ios that exist, methodological work investigating suitable
design and analysis strategies cannot be focused appro-
priately. The specific objectives of this systematic review
were to:
1 Explore how trials of proportionate interventions are
being designed in practice
2 Review the type of statistical design and analysis
methods being implemented in trials involving
staged proportionate interventions
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3 Review whether trials of proportionate interventions
are being analysed differently to trials of
non-proportional interventions and if the
component parts are considered in the analysis.
Methods
Details of the protocol for this systematic review were
registered on PROSPERO (CRD42016033781). We con-
ducted the review according to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for reporting systematic reviews
where relevant [7]. A completed PRISMA checklist [7] is
available as Additional file 1.
Literature search
Proportionate interventions evaluated in a randomised
controlled trial between 2010 and 2015 inclusive were
sought. Electronic searches were undertaken using the
databases: MEDLINE (OvidSP), Web of Science (Core
Collection) and PsycINFO. The search terms were any
of the following in the title or abstract: ‘proportionate
universalism’, ‘proportionate intervention’, ‘proportionate
treatment’, ‘staged intervention’, ‘staged treatment’, ‘adap-
tive treatment regimen’, ‘adaptive intervention’, ‘adaptive
treatment strategy’, ‘dynamic treatment regimen’, ‘multi-
level intervention’ or ‘stepped care’. The search strat-
egy was based on the Cochrane Highly Sensitive Search
Strategies for identifying randomised trials [8]. The start
date of the 6-year time frame was chosen based on the
2010 publication date of the Marmot review [2], which
referred to proportionate universalism. We anticipated
no trials would use the term ‘proportionate universalism’
prior to this review and anticipated an increase in the
use of such interventions post publication of the Marmot
Review [2]. The final search was conducted in March
2016 (after piloting and refining the search strategy).
Search strategies were developed that were relevant to
the database requirements (see Fig. 1 for the MEDLINE
search strategy). The intention of the systematic review
was to provide a thorough overview of the types of trials of
proportionate interventions being used in practice but not
to be exhaustive; therefore, additional hand searching or
searching of clinical trial registers was not incorporated.
Eligibility criteria
All search results that were trials or pilot studies (includ-
ing protocols) that evaluated interventions delivered
proportionate to need were eligible. An intervention pro-
portionate to need was defined as one in which there is a
variation in the intervention dependent upon either an inter-
mediate or primary outcome measured prior to the study
endpoint. There should be decision stages and at each
stage there should be treatment options based on tailoring
variables and predefined decision rules. Interventions that
are tailored without decision rules were excluded from
this review. We excluded observational studies and those
not in English. Where more than one article for a sin-
gle study was found, the main article of published results
was included if available and if it superseded any protocol
or cost-effectiveness study. We considered all therapeutic
areas and imposed no restrictions on the participants.
Quality control
We did not undertake a quality assessment of the
identified studies as the purpose of this review was to
understand what interventions and trial designs are being
Fig. 1MEDLINE search strategy
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used in practice and how they are being designed and
analysed.
Study selection
Study selection based on the eligibility criteria was per-
formed by review author JCa, who identified relevant
results. All duplicates were removed. At the initial screen-
ing stage, titles and abstracts were assessed to identify if
the study was eligible. The full articles of studies meeting
the review criteria were obtained and inspected to iden-
tify relevant studies that fulfil the inclusion criteria. Two
second authors (JCo and MDT) reviewed a random sam-
ple of ten results each to assess agreement and the clarity
of eligibility criteria.
Data extraction and synthesis
A data extraction tool was developed for this review in an
Excel spreadsheet. The data extraction tool was piloted by
reviewers JCa, JCo and MDT and refined based on feed-
back. This review evaluated designs and methods used
in proportionate intervention trials; therefore, a meta-
analysis was not appropriate. We collected the following
information with the data extraction tool: publication
year, location of study (country), therapeutic area, type of
study (trial results, protocol or secondary analysis), design
type, aim, eligibility criteria, intervention, tailoring vari-
able, decision rules, number of decision stages, control
intervention, final study follow-up period, sample size,
primary outcome, overall statistical model, and whether
an analysis of different stages was undertaken.
The review results were presented using summary
statistics. A narrative synthesis describes any similarities
and differences among the included studies. We grouped
studies by design type, and study characteristics were
tabulated to allow a comparison of the main features.
Results
Study selection
Figure 2 presents the process of study selection in this
systematic review. Of the 531 unique records identified
from the database search, we identified 44 eligible studies
(all papers included are listed in Additional file 2). These
44 studies consisted of 28 trial results, 13 protocols and
three secondary analyses. The narrative syntheses have
been split into two subcategories by type of study design,
stepped care and optimal treatment strategy. Inclusion
of a control arm was not required for eligibility. Due to
the nature of assessing proportionate interventions, some
results did not include a control arm, either due to ethi-
cal arguments or because the objective was to identify an
optimal treatment strategy.
Study characteristics
Table 1 presents an overview of the included studies.
There were 18 studies based in the United States, 14 in
the Netherlands, one in the Netherlands and Belgium, two
in each of Australia, England and Scotland, Norway and
Sweden, and three based in other countries (India, Nigeria
and a multi-site study in France, Hungary, Romania and
Slovakia).
The median number of decision stages (points at which
the intervention was adapted according to need based on
predefined decision rules) was 2 (interquartile range 1 to 3).
The median length of trial follow-up was 12 months
(interquartile range 6 to 12 months) and the median
sample size was 236 (interquartile range 150 to 387).
Stepped care
Table 2 is a summary of the included stepped-care studies.
A total of 84% (37 of 44) of the studies followed a stepped-
care model for the intervention. The stepped-care model
is recommended by the National Institute for Health and
Care Excellence (NICE) [9] for the provision of services
for common mental health disorders. In a stepped-care
model, the least intensive intervention (or the lowest
level of intervention) is delivered first to all patients,
and patients step up or down the stepped-care treatment
pathway dependent upon their response to the previous
intervention step.
Figure 3 represents the flow of patients through an
example of a typical stepped-care trial with three treat-
ment steps. The key principles of stepped care are
to provide the most appropriate and best treatment
according to need, to reduce the burden on patients by
providing only the treatment required and to improve
cost-effectiveness by providing the level of intervention
required for a positive outcome [9]. The reduction of costs
for those who respond to lower-intensity interventions
can free up resources for those who requiremore intensive
treatment [10].
The majority of stepped-care studies (73%; 27 of 37)
focussed on the therapeutic areas of depression, anxi-
ety, stress or some form of mental health disorder. Other
therapeutic areas targeted included: weight loss [11, 12],
alcohol consumption [13, 14], eating disorders [15, 16],
whiplash injuries [17], bloodpressure control [18], resilience
and well-being of families living with childhood chronic
illness [19], and impairment in older dizzy people [20].
The interventions often involved some form of watch-
ful waiting period for the first step followed by regular
monitoring at predefined follow-up times of an outcome
measure (either secondary or primary). Based on this out-
come measure, decisions were made whether to progress
to the next step or not. This process continued for how-
ever many steps were included in the intervention. Based
on the individual’s outcome, at each decision stage the
options for the following step were often: (1) a choice
of treatments, (2) continue with the same treatment, (3)
augment the treatment or (4) discontinue the treatment
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Fig. 2 PRISMA study flow diagram. Number of records identified, included and excluded during the literature search
altogether. The progression of treatment steps for inter-
ventions aimed at mental health disorders commonly
included a watchful waiting period, bibliotherapy, guided
self-help, or psychotherapy sessions (either individual or
group based), with a possible progression to medication
(for example, antidepressants).
Control conditions were generally usual care or
enhanced usual care with others being assessment only
[19], waiting list control [21] or the active treatment deliv-
ered in a non-stepped model [12, 22, 23]. Four of the
stepped-care trials had no explicit control [18, 24–26].
In one study, it was argued that the lack of control
was partially inherent to the stepped-care design since it
was unethical to assign individuals to a waiting list con-
trol after the first treatment step if they needed further
treatment [26].
Measures were taken at baseline, at each decision stage
and after the end of the final intervention stage. Generally,
follow-up measures were also taken a number of months
after completion of the interventions to assess if the effects
were sustained. Our search results included both individ-
ually randomised and cluster-randomised trials.
A variety of statistical analysis methods were used,
dependent upon the outcome measures and main aims.
Longitudinal data were incorporated into many of the
analyses. Mixed-effects models, containing both fixed
and random effects, were used as the statistical analysis
method in 38% of studies (14 of 37; Table 2). They were
used to account for both longitudinal data and the cluster-
ing effects of National Health Service (NHS) trusts, ther-
apists and other health professionals. Repeated measures
analysis of variance (ANOVA) was used in three studies
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Table 1 Overview of studies included in the systematic review
First author Datea Therapeutic area Country Follow-upb Nc
Ell [54] 2010 Depression and anxiety United States 12 387
Van’t
Veer-Tazelaar [55]
2010 Depression and anxiety The Netherlands 12 170
Braamse [56] 2010 Distress after autologous stem cell
transplantation
The Netherlands 10 286
Patel [57] 2010 Depression and anxiety India 12 2796
Gilliam [25] 2010 Obsessive–compulsive disorder United States 3 14
Kay-Lambkin [58] 2010 Depression among methamphetamine
users
Australia 5 8
Richter [18] 2011 Blood pressure France, Hungary, Romania, Slovakia 6 256
Weissd [32] 2011 Prescription opioid dependence United States 6 653
Mitchell [16] 2011 Bulimia nervosa United States 12 293
Seekles [59] 2011 Depression and anxiety The Netherlands 6 120
Tolin [23] 2011 Obsessive–compulsive disorder United States 3 34
van der Leeden
[26]
2011 Anxiety in children The Netherlands 6 133
Apil [60] 2012 Depression The Netherlands 12 136
Karp [61] 2012 Depression and chronic pain United States 12 250
Shortreed d [33] 2012 Schizophrenia United States 18 1460
Dozeman [62] 2012 Depression and anxiety The Netherlands 10 185
Nordin [24] 2012 Stress management of cancer patients Sweden 12 300
Jakicic [11] 2012 Weight loss United States 18 363
Wangd [34] 2012 Oncology United States 7 150
Pommer [63] 2012 Depression and anxiety in patients with
asthma or COPD
The Netherlands 24 160
Lamb [17] 2012 Whiplash injuries England and Scotland 12 3851
Krebber [27] 2012 Distress in head and neck and lung cancer
patients
The Netherlands 12 176
Borsari [21] 2012 Alcohol consumption United States 9 598
Rosed [30] 2013 Smoking cessation United States 6 606
Watson [13] 2013 Alcohol consumption England and Scotland 12 529
Oosterbaan [29] 2013 Common mental disorders The Netherlands 8 163
van Dijk [64] 2013 Depression among patients with diabetes
and/or coronary heart disease
The Netherlands 12 236
Arving [65] 2013 Stress management of cancer patients Norway 24 300
Mattsson [28] 2013 Depression and anxiety Sweden 24 200
Carels [12] 2013 Weight loss United States 4 52
van der Aa [66] 2013 Depression and anxiety The Netherlands and Belgium 24 230
Kasarid [31] 2014 Communication for minimally verbal
children with autism
United States 8 61
Muntingh [67] 2014 Panic and anxiety The Netherlands 12 180
Kilbourned [36] 2014 Mood disorder United States 24 1600
Hamall [19] 2014 Families living with childhood chronic illness Australia 6 1050
Gureje [68] 2015 Depression Nigeria 12 1190
Stoop [69] 2015 Depression and anxiety in patients with
diabetes, asthma or COPD
The Netherlands 18 46
Stam [20] 2015 Impairment in older dizzy people The Netherlands 12 300
Candlish et al. Trials          (2019) 20:151 Page 7 of 20
Table 1 Overview of studies included in the systematic review (Continued)
First author Datea Therapeutic area Country Follow-upb Nc
Lock [15] 2015 Anorexia nervosa United States 6 45
Schuurhuizen
[70]
2015 Distress in patients with metastatic
colorectal cancer
The Netherlands 11 715
Haug [71] 2015 Panic and anxiety Norway 12 173
Salloum [72] 2015 Post-traumatic stress in children United States 3 53
Wud [35] 2015 Bipolar disorder United States 3 365
Painter [73] 2015 Depression in HIV patients United States 12 249
COPD chronic obstructive pulmonary disease
aPublication date
bFinal follow-up post baseline in months
cSample size
dOptimal-treatment strategy subcategory
[25, 27, 28]; however, this method does not successfully
deal with missing values. In contrast, mixed-effects mod-
els assume data are missing at random and they allow for
imbalanced or missing observations within patient.
Six stepped-care studies included or planned some form
of analysis of the different stages. These included:
1. summaries of outcome measures presented per
treatment step [18],
2. an analysis of outcomes after steps 1 and 2 [29],
3. an analysis at the end of each step and the end of the
whole intervention as well as a comparison of
differences in weight loss and self-monitoring
characteristics between those who were stepped
down and those who continued to receive treatment
in the stepped-care arm [12],
4. a planned analysis of demographic data to compare
the characteristics of those who agreed to participate
in steps 2 and 3 compared to those who declined (for
eligible patients) [19],
5. the percentages of children free of any anxiety
disorder after each treatment phase and by
intervention [26],
6. analysis of outcomes after step 1 and analysis of
outcomes after step 2 adjusting for the intervention
received in step 1 and any interactions between the
step 1 and step 2 interventions [17].
The objectives of Lamb et al. [17] were to evaluate the
effectiveness of step 1, step 2, and the combined effects
of the treatments together. This was made possible by
designing two linked pragmatic randomised controlled
trials. In step 1, emergency departments were cluster
randomised to theWhiplash Book or usual care, and indi-
vidual consent was not sought at this stage. In step 2,
participants who received either of the step 1 treatments
and were eligible after step 1 (persistent symptoms at 3
weeks) were individually randomised at step 2 to either
one physiotherapist advice session or up to six physiother-
apist advice sessions.
Optimal adaptive treatment strategy
Table 3 presents a summary of the studies of optimal adap-
tive treatment strategies. A total of 16% (7 of 44) of the
review studies were aimed at finding an optimal treat-
ment strategy. Treatments consist of more than one phase.
Unlike most of the stepped-care studies, randomisation
occurs more than once and there was often no true con-
trol, since the different adaptive treatment strategies were
compared to one another. Six of the studies were explic-
itly defined as SMARTs, with the other study based on
a two-phase trial design evaluating an adaptive smoking
cessation treatment strategy [30].
The optimal treatment strategy studies included three
with trial results [30–32], three secondary analyses of tri-
als [33–35] and one trial protocol [36]. All seven studies
were based in the United States. Therapeutic areas cov-
ered were oncology [34], schizophrenia [33], depression
and anxiety [36], bipolar disorder [35], patients dependent
on prescription opioids [32], smoking cessation [30] and
communication for minimally verbal children [31].
Five of the optimal treatment strategy studies were
based on two phases or stages of intervention and two
studies used a three-phase design [34, 36]. Ameasurement
at the end of each phase was used to assess the response
and thus, progression to the next phase. Participants were
generally randomised to phase 1 treatments. If they were
classified as responders to phase 1, they continued this
treatment whereas non-responders were randomised to
the following phase treatments. An example design is rep-
resented in Fig. 4. The number of treatments at each
randomisation phase varied greatly between studies. In
phase 1, there were between two and six treatments ran-
domised (two treatments [31, 32, 36], three treatments
[35], four treatments [34] or five treatments [33]). No con-
trol group was used in four of the studies [31, 33, 34, 36].
One study used a placebo in stage 1 [35] and usual care
was used in another [32].
In general, more complex analysis methods were used
for the optimal adaptive treatment strategies compared
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Table 2 Characteristics of included stepped-care studies
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
Ell [54] Stepped care, three steps: (1) based on patient
preference, patients start PST or antidepressant
medication, 8 weeks, (2) a different antidepressant
medication or the addition of antidepressant
medication or PST, 4 weeks, (3) considered for
additional PST, augmentation of low-dose trazodone
for insomnia and referral to speciality mental health
care
50% SCL-20 reduction Depression remission was
assessed by SCL-20 < 0.5
or PHQ-9 < 5
Logistic regression model used to
compare the odds of achieving
clinically meaningful improvement
between treatment groups
No
Van’t Veer-Tazelaar [55] Stepped care, four steps: (1) watchful waiting, (2)
bibliotherapy, (3) PST, (4) antidepressant medication;
stages were in 3-month cycles
CES-D < 16 MINI/DSM-IV diagnostic
status of depressive and
anxiety disorders
Incremental effectiveness
computed as the difference in the
probability of a disorder-free period
between groups
No
Braamse [56] Stepped care, two steps: (1) internet-based self-help
programme, (2) contracting, individual face-to-face
counselling, medication or referral to other services
PHQ-9≤ 10 and/or HADS < 8
and/or STAI < 40
Psychological distress
using HADS and physical
role function using
EORTC-QLQ-C30
ANOVA No
Patel [57] Stepped care, four steps: (1) psychoeducation, (2)
antidepressants, (3) interpersonal psychotherapy in
addition to antidepressants or an alternative to
antidepressants for those who did not respond to
them, (4) referral to psychiatrist
Varying ICD-10 diagnosis Chi-squared and t-tests;
mixed-effects models for
longitudinal data
No
Gilliam [25] Stepped care, two steps: (1) short therapist sessions
and bibliotherapy, (2) longer therapist-directed
sessions
Y-BOCS reduction≥5 points plus a
post-treatment score of≤13
Y-BOCS total score and
the clinician’s CGI severity
rating
Repeated measures ANOVA No
Kay-Lambkin [58] Stepped care, four steps: (1) brief integrated CBT/MI
intervention, one session, (2) four CBT/MI sessions, (3)
four CBT/MI sessions, (4) four CBT/MI sessions
Varying Depression and
methamphetamine use
Small sample size, so no statistical
analyses
No
Richter [18] Stepped care, six steps: incremental therapy included
the following add-on therapies at 4-week intervals:
aliskiren 150–300 mg once daily, hydrochlorothiazide
12.5–25 mg once daily and finally amlodipine 5–10
mg once daily, as needed
Meet the target blood pressure at
4-week intervals
Estimated cumulative
probability of patients
achieving blood pressure
target
Probability of reaching the blood
pressure target, assessed by
estimating control rates of patients
who reached target per visit using
life-table survivor estimates at each
visit; summaries presented of
change in blood pressure per
treatment step
Yes
Mitchell [16] Stepped care, three steps: (1) therapist-assisted
self-help for 18 weeks, (2) fluoxetine until 1-year
follow-up, (3) full CBT for 6 months
70% or more reduction in
frequency of purging by the end of
Session 6
Recovery (no binge eating
or purging behaviours in
the past 28 days);
remission (no longer
meeting DSM-IV criteria)
ANOVA with the site× treatment
interaction
No
Seekles [59] Stepped care, four steps: (1) watchful waiting, 4
weeks, (2) guided self-help, (3) five short face-to-face
PST sessions, (4) pharmacotherapy and/or specialised
mental health care
IDS < 14 and HADS < 8 and WSAS
< 6
IDS and HADS t-tests to compare scores between
two groups
No
Tolin [23] Stepped care, two steps: (1) bibliotherapy, 6 weeks,
(2) therapist-directed ERP sessions
Y-BOCS≥5 and≤13 Y-BOCS and cost Mixed-effects model No
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Table 2 Characteristics of included stepped-care studies (Continued)
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
van der Leeden [26] Stepped care, four steps: (1) randomised to group or
individual CBT sessions for children and parents, (2)
five manual-based PCTA sessions, (3) additional five
PCTA sessions
Children diagnosed with an anxiety
disorder or who scored below the
cut-off of the MASC
Change in proportion of
children with any DSM-IV
anxiety disorder
Percentages of children free of any
anxiety disorder after each
treatment phase and by
intervention, e.g. intervention 1
only, 1 and 2, 1–3 and all combined;
mixed-effects models for changes
on the continuous variables
Yes
Apil [60] Stepped care, four steps: (1) watchful waiting, 6
weeks, (2) bibliotherapy self-help booklet, 6 weeks,
(3) 12 individual CBT weekly sessions, (4) referral to
physician or psychotherapist for any indicated
treatment
CES-D≤16 Incidence of new
depressive episode
Feasibility evaluated descriptively;
chi-squared test used to test if
selective drop-out biased results of
incidence of a new depressive
episode
No
Karp [61] Stepped care, two steps: (1) 6 weeks open treatment
with venlafaxine xr 150 mg/day and supportive
management, (2) 14 weeks in which non-responders
are randomised to high-dose venlafaxine xr (up to
300 mg/day) with PST for depression and pain or
high-dose venlafaxine xr and continued supportive
management
PHQ-9 of≤5 for 2 weeks and at
least 30% improvement in the
average numeric rating scale for
pain
Univariate pain and
depression response and
both observed and
self-report disability
Number needed to treat between
two interventions; repeated
measures mixed-effect models for
self-reported and observed
physical disability between the two
interventions across time
No
Dozeman [62] Stepped care, four steps: (1) watchful waiting, 3
months, (2) activity scheduling, 3 months, (3) life
review and consultation with GP, 3 months, (4)
consultation with GP to discuss further treatment, 3
months
Improvement of≥5 points on
CES-D
Incidence of major
depressive disorder or
anxiety disorder using
MINI
Incidence rate ratio using an
unadjusted and adjusted Poisson
regression analysis of MINI/DSM-IV
depressive and anxiety cumulative
incidence (1= developed a
disorder and 0= remained
disorder-free) on the treatment
indicator
No
Nordin [24] Stepped care, two steps: (1) low-intensity
stress-management intervention given to all patients,
(2a) more intensive group stress management
treatment, (2b) more intensive individual stress
management treatment
Decrease in stress-related
symptoms measured by IES or
HADS from clinical levels to normal
results
Subjective distress
(intrusion and avoidance)
assessed by IES
Repeated measures ANOVA
(continuous variables) and
chi-squared test (categorical
variables)
No
Jakicic [11] Stepped care, six steps: (1) monthly group
intervention session plus weekly mailed lessons and
submission of self-monitoring diaries, (2) continue
step 1 plus 10-minute monthly telephone contact, (3)
step 2 plus second 10-minute telephone contact
each month, (4) step 3 plus 1 individual in-person
intervention contact per month, (5) step 4 plus meal
replacement shakes and bars provided to replace
one meal and one snack per day, (6) step 5 plus
replace one telephone contact with second
individual session per month; modified based on
weight-loss achievement at 3-month intervals
Weight-loss goals 5% at 3 months,
7% at 6 months, 10% at 9 months,
and remained at 10% at 12, 15 and
18 months
Change in weight over 18
months
t-test to compare mean weight loss
between groups; mixed-effects
models for longitudinal data
No
Pommer [63] Stepped care, three steps: (1) four sessions of
extensive psycho-education, (2) a course on coping
with depression and/or anxiety, 10 consultations, (3)
coaching (six booster sessions on top of step 2)
complemented with optional antidepressant and/or
anxiolytic medication
PHQ-9 < 7 and/or GAD-7 < 8 PHQ-9, GAD-7 and MINI Chi-squared and t-tests;
mixed-effects models for
longitudinal data
No
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Table 2 Characteristics of included stepped-care studies (Continued)
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
Lamb [17] Stepped care, two steps: (1) Whiplash Book advice or
active management advice, (2a) single session of
physiotherapist advice or (2b) up to six sessions of
physiotherapy
Non-response if persistent
symptoms 3 weeks after
emergency department
attendance (WAD grades I–III)
Neck Disability Index Mixed models to account for
clustering effects from NHS trusts
and therapists in step 2
Yes
Krebber [27] Stepped care, four steps: (1) watchful waiting, 2
weeks, (2) guided self-help via internet or booklet, 5
weeks, plus six phone or email coaching sessions, (3)
PST administered by a specialised nurse, (4)
specialised psychological intervention or
antidepressant medication chosen in cooperation
between patient and care co-ordinator
HADS-A or HADS-D≤ 7 HADS Repeated measures ANOVA
(continuous outcomes);
generalised estimating equations
used to evaluate longitudinal
changes
No
Borsari [21] Stepped care, two steps: (1) brief advice session, (2a)
brief motivational intervention, (2b) assessment only
Non-response if student has heavy
episodic drinking≥4 and/or
alcohol-related consequences≥5
in the past month they were
randomised to receive step 2 or
control (assessment only)
Heavy episodic drinking
and peak blood alcohol
content
Comparison of outcomes at 3, 6
and 9 months between those
assigned to (2a) or (2b) using
generalised estimating equations
for longitudinal data
Yes
Watson [13] Stepped care, three steps: (1) behavioural change
counselling, one session, (2) motivational
enhancement therapy, three sessions, (3) local
specialist alcohol services
Three-item AUDIT-C <5 Average drinks per day Linear mixed model, to account for
variation in GP practice and
allocated therapist
No
Oosterbaan [29] Stepped care, two steps: (1) self-help course, (2) CBT
in combination with antidepressant medication
CGI-S < 3 % of patients responding
to and remitting after
treatment measured using
CGI-S
Logistic mixed-effects models;
analysis after steps 1 and 2
Yes
van Dijk [64] Stepped care, four steps: (1) watchful waiting, (2)
guided self-help, (3) PST, (4) referral to GP
PHQ-9≥ 6 Cumulative incidence of
DSM-IV major depressive
disorder using MINI
Logistic mixed-effects models No
Arving [65] Stepped care, two steps: (1) low-intensity stress
management consisting of two counselling sessions
over 6 weeks, (2) more intensive stress-management
treatment consisting of 4–7 sessions
IES and HADS score at 6-week
assessment not clinically significant
Avoidance and intrusions Repeated measures ANOVA
(continuous variables) and
chi-squared test (categorical
variables)
No
Mattsson [28] Stepped care, two steps: (1) self-help material, chat
forum and FAQ section, (2) CBT
HADS subscale <7 at 1, 4 or 7
months after inclusion
HADS, 20% change as
clinically relevant
Repeated measures ANOVA to
compare intervention and control
group regarding anxiety,
depression, post-traumatic stress
and health-related QoL
No
Carels [12] Stepped care, three steps: (1) group-based
behavioural weight-loss programme, 6 weeks, (2a)
behavioural weight-loss programme, 6 weeks or (2b)
self-help, (3a) behavioural weight-loss programme, 6
weeks or (3b) self-help
Meet the 3% weight-loss target % weight loss Repeated measures ANOVA
(continuous variables) and
chi-squared test (categorical
variables) to compare differences
between treatment groups at the
end of each stage and the end of
the whole intervention
Yes
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Table 2 Characteristics of included stepped-care studies (Continued)
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
van der Aa [66] Stepped care, four steps: (1) watchful waiting, (2)
guided self-help, (3) PST, (4) referral to GP
CES-D < 16 or HADS-A < 7 MINI Survival analysis and mixed-effects
model
No
Muntingh [67] Stepped care, four steps: (1) guided self-help, (2) CBT,
six sessions, (3) antidepressant medication prescribed
by GP, (4) optimisation of medication in primary care
or referral to secondary care
50% reduction in BAI score and BAI
≤ 11
BAI score Difference in gain BAI gain scores
from baseline; inverse probability
weighting used, accounts for
variation in receiving treatment
No
Hamall [19] Stepped care, three steps: (1) family resilience and
well-being fact sheet, (2) family resilience and
well-being activity booklet, (3) family resilience
information support group or waiting list control
Step 2: parents eligible if have a
child attending one of four selected
outpatient clinics at the paediatric
hospital. Step 3: eligible if K10≥ 15
Parental well-being (K10);
family functioning
(McMasters Family
Assessment Device); social
connectedness (Medical
Outcomes Study Social
Support Survey); family
beliefs
Descriptive statistics used for step
1. ANOVA for effect of booklet
intervention for all participants in
step 2 and sustained change tested
using a repeated measures
mixed-effects model for the
participants who did not move into
step 3. ANOVA to examine
additional effect of the information
support group relative to waiting
list control group
Yes
Gureje [68] Stepped care, three steps: (1a) eight weekly
psychoeducation and PST sessions, (1b) eight weekly
psychoeducation and PST sessions plus doctor’s
advice on treatment, (2a) four monthly
psychoeducation and weekly PST sessions, (2b) eight
weekly psychoeducation and PST sessions, (2c)
consult doctor plus eight weekly psychoeducation
and PST sessions, (3a) four monthly psychoeducation
and weekly PST sessions, (3b) consult doctor plus
eight weekly psychoeducation and PST sessions
Step 1: (1a) if PHQ-9 = 11–14 , (1b) if
PHQ-9≥ 18. Step 2: (2a) PHQ-9 <
11, (2b) PHQ-9 = 11–17, (2c) PHQ-9
≥ 18. Step 3: (3a) PHQ-9 < 11, (3b)
PHQ-9≥ 11
Recovery from depression
at 12 months as shown by
PHQ-9≤ 6
Mixed-effects regression model No
Stoop [69] Stepped care, three steps: (1) four weekly
psychoeducation individual meetings, (2) 10 weekly
individual meetings covering the coping with
depression/anxiety course, (3) advice to meet GP to
discuss optional medication and six booster sessions
during 6 months; followed by monitoring of
symptoms of depression or anxiety if remission
PHQ-9 < 7 and/or GAD-7 < 8 Symptoms of anxiety and
depression after 12
months of intervention
and 6 months
post-intervention
ANCOVA and clinical significance in
terms of effect size
No
Stam [20] Risk-factor-guided intervention including: (1)
medication adjustment if three or more prescribed
fall-risk-increasing drugs, (2) stepped care if anxiety
disorder or depression, (3) exercise therapy if
impaired functional mobility; those eligible for more
than one intervention start them at the same time.
Stepped care, four steps: (1) watchful waiting, 6
weeks, (2) guided self-help treatment, 6 weeks, (3)
PST maximum six sessions, (4) referral to GP
GAD-7 < 10, PHQ-9 < 10, or
positive PHQ-PD score
Dizziness-related
impairment, assessed
using the Dizziness
Handicap Inventory
Mixed-effects models for
longitudinal data to compare
intervention and control groups,
regardless of number of
interventions; separate subgroup
analyses for three groups that
received one of three interventions
No
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Table 2 Characteristics of included stepped-care studies (Continued)
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
Lock [15] Adaptive intervention, intensive family coaching,
consisting of FBT/IPC: four sessions of FBT plus three
sessions of IPC
Weight gain≥2.3 kg after FBT,
proceed to IPC
Retentions and treatment
use, suitability and
expectancy, clinical
outcomes, changes in
parental self-efficacy
Feasibility and acceptability
compared across the randomised
groups (FBT versus FBT/IPC) using
chi-squared test and t-test
No
Schuurhuizen [70] Targeted selection by a nurse (HADS≥ 13 or
Lastmeter≥ 5), enhanced care (treatment managed
by a trained nurse) and stepped care. Stepped care,
four steps: (1) watchful waiting, 3 weeks, (2) guided
self-help programme, 5–7 weeks, maximum six
sessions in 10 weeks, (3) face-to-face PST, (4)
psychotherapy, medication or a referral to other
services (e.g. social work)
HADS < 13 Psychological distress
measured by HADS
ANCOVA for difference between
groups; time patients entered
stepped care and the response to
treatment (progression or not) are
accounted for via a covariate
No
Haug [71] Stepped care, three steps: (1) short psychoeducation,
(2) 10 weeks’ internet-based self-help programme, (3)
12 weeks of individual CBT
Two out of three of the following
criteria: (1) loss of primary diagnosis
(SCID-I), (2) CSR≤ 3 and reduced
by at least two points, (3) for panic
disorder, BSQ≤ 2.5, and for
seasonal affective disorder, SPS≤
25
CSR, a 0–8 severity rating
of the primary anxiety
diagnosis
Multiple regression analyses
enhanced with the full information;
maximum likelihood estimation of
missing data
No
Salloum [72] Stepped care, two steps: (1) three therapist-led
sessions, 11 parent–child meetings at home over 6
weeks using a workbook, weekly brief phone
support, online psychoeducation information and
video demonstrations, (2) nine trauma-focussed CBT
sessions
PTS≤ 3, or TSCYC-PTS≤ 39 and an
CGI-I rating of 3, 2 or 1
TSCYC-PTS Linear mixed-effects models
(continuous outcomes);
generalised linear mixed-effects
models (non-continuous outcome)
for longitudinal data
No
Painter [73] Stepped care, five steps: (1) watchful waiting, (2)
depression care team treatment suggestions
(counselling or pharmacotherapy, considering
participant preference), (3) pharmacotherapy
suggestions after review of treatment history, (4)
combination pharmacotherapy and speciality mental
health counselling, (5) referral to speciality mental
health
Non-response defined on five
different measures: antidepressant
adherence, counselling
non-adherence, report of severe
adverse effects, increase in PHQ-9
from baseline by≥5 or <50%
decrease from enrolment PHQ-9
Quality-adjusted life years
and percentage of
participants with
depression treatment
response
Generalised linear models to
calculate predicted expenditure for
each participant to determine
incremental cost; logistic regression
models to compare the odds of
achieving clinically meaningful
improvement (SCL-20 improved by
≥50%) between groups
No
ANCOVA Analysis of covariance; ANOVA analysis of variance; AUDIT-C Alcohol Use Disorders Identification Test, Consumption; BAI Beck Anxiety Inventory; BSQ Body Sensations Questionnaire; CBT cognitive behavioural therapy; CES-D
Epidemiologic Studies Depression Scale; CGI Clinical Global Impression; CGI-I Clinical Global Impression, Improvement Scale; CGI-S Clinical Global Impression, Severity Scale; CSR Clinicians’ Severity Rating; DSM-IV Diagnostic and
Statistical Manual of Mental Disorders; EORTC-QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; FAQ Frequently asked questions; FBT Family-based Treatment; GAD-7 Generalised
Anxiety Disorder, 7; GP general practitioner; HADS Hospital Anxiety and Depression Scale; HADS-A Hospital Anxiety and Depression Scale, Anxiety; HADS-D Hospital Anxiety and Depression Scale, Depression; ICD-10 International
Statistical Classification of Diseases and Related Health Problems, 10th revision; IDS Inventory of Depressive Symptomatology; IE; IES Impact of Events Scale; IPC Intensive Parental Coaching; K10 Kessler Psychological Distress Scale;
MASC Multidimensional Anxiety Scale for Children;MImotivational interview;MINIMini International Neuropsychiatric Interview; NHS National Health Service; PCTA Parent–Child Treatment for Anxiety; PHQ-9 Patient Health
Questionnaire; PHQ-PD Patient Health Questionnaire, Panic Disorder Subscale; PST problem-solving treatment; QoL quality of life; SCID-I Structured Clinical Interview for DSM-IV; SCL-20 20-item Symptom Checklist Depression Scale; SPS
Sensory Processing Sensitivity; STAI State-Trait Anxiety Inventory; TSCYC-PTS Trauma Symptom Checklist for Young Children, Post-Traumatic Stress Subscale;WADWhiplash-Associated Disorders;WSASWork and Social Adjustment
Scale; Y-BOCS Yale–Brown Obsessive–Compulsive Scale
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Fig. 3 Example of a stepped-care trial with three steps and the option to rejoin treatment if relapse occurs. R randomise
to the stepped-care trials. Inverse probability weighting
methods were used to estimate the outcome means asso-
ciated with each of the two-stage dynamic treatment
regimes [34]. A comparison of two treatment condi-
tions was done using the phase 2 endpoint and gener-
alised estimating equations (to account for correlation
among measurements of patients from the same site)
[32]. Other methods to estimate the optimal treatment
strategy included: Q-learning [35], marginal structural
models [33] and mixed-effects models [31, 36]. The stud-
ies were generally interested in estimating the optimal
treatment strategy as a whole rather than considering the
effects of each treatment stage. Different stages of the
interventions were considered in some analyses, includ-
ing measuring those who responded after stage 1 and
randomising those who did not respond to stage 2 [32]
and weighted regression to compare outcomes between
the three embedded adaptive treatments, including an
indicator for stage 1 and stage 2 treatments and account-
ing for the probability of a participant following their
assigned sequence of treatments based on randomisation
sequence [31].
Discussion
Main findings
The results suggest that trials are being designed in vari-
ous therapeutic areas that fit the proportionate universal
framework. Most results were conducted in developed
countries. The term ‘proportionate universalism’ was not
used within the identified studies. Other terminology
used included: stepped care, adaptive treatment strategy,
dynamic treatment regimen and SMART. In the review,
eligible studies fell into twomain subcategories of designs:
trials using the stepped-care design (to provide treatment
dependent on need) or aimed at identifying an optimal
treatment strategy (when more than one treatment was
available at various stages and administered dependent
upon need). The stepped-care model begins with a lower
level of intervention at the first step and treatment is
administered at further steps only to those in need. Ran-
domisation generally occurs only at baseline. The optimal
treatment strategy trials inform decisions on how and
when to alter treatment. They generally involved ran-
domisation at each stage dependent upon the response at
the end of the previous stage.
Mental health disorders were the most common thera-
peutic area of research in this review. This is most likely
because a large majority of the results were stepped-care
trials, which is a NICE-recommended pathway for mental
health care [9]. Reasons for using a proportionate inter-
vention were mainly based around costs and providing the
level of care required by an individual. This is particularly
relevant inmental health and complex interventions, since
they are often fairly resource-intensive (both in time and
costs).
The statistical methods used varied greatly based on
the outcome measures, though longitudinal data are
generally a feature of trials of a proportionate inter-
vention. The trials need to update and measure the
adjusting needs of patients during delivery of the inter-
vention. ANOVA and repeated measures ANOVA were
used in a number of analyses. However, these are
not recommended as a general approach for longitu-
dinal data due to the following limitations: (1) they
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Table 3 Characteristics of included optimal treatment strategy studies
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
Weiss [32] Two-stage intervention. Stage 1: buprenorphine–
naloxone induction, 2 weeks of stabilisation, a 2-week
taper and 8 weeks of follow-up. Stage 2: 12 weeks of
buprenorphine–naloxone stabilisation, a 4-week
taper and 8 weeks of follow-up. In each phase,
patients were randomised to (1) standard medical
management or (2) standard medical management
plus individual drug counselling
Stage 1: self-reported opioid use on
≤4 days in a month, absence of
two consecutive opioid-positive
urine test results, no additional
substance use disorder treatment
and≤1 missing urine sample.
Stage 2: abstaining from opioids
during week 12 and during≥2 of
the previous 3 weeks
Composite measures indicating
minimal or no opioid use based on
urine test-confirmed self-reports
Compare two treatment conditions
using the stage 2 endpoint;
generalised estimating equations
to account for clustering of
patients by site
Yes
Shortreed [33] Two-stage intervention. Initially randomised to newer
atypical antipsychotics or to perphenazine. Patients
randomised at stage 1 to perphenazine who
discontinue were randomised to a newer atypical
antipsychotic. Patients randomised at stage 1 to a
newer atypical antipsychotic who discontinue were
given the choice of two randomisation arms: (1) with
ziprasidone, olanzapine, risperidone or quetiapine,
excluding their previous treatment or (2) with
clozapine, olanzapine, risperidone or quetiapine,
again excluding their previous treatment. Dissatisfied
patients could opt to switch treatment again; at this
stage treatment was neither randomised nor blinded
Non-response if patient
discontinues treatment and then
eligible for randomisation to next
stage
12-month PANSS score and
12-month QoL score
Marginal structural modelling using
a weighted analysis to compare
treatment regimes: the always
atypical antipsychotic regime or the
perphenazine and atypical regime
No
Wang [34] Three-stage intervention. Stage 1: randomised to one
of four combination chemotherapies. Stage 2: (2a)
responders receive second course of same chemo,
(2b) non-responders randomised to second-line
treatment. Stage 3: After (2a): (3a) responders receive
second course of same treatment, (3b) if treatment
not finished. After (2b): (3c) if overall success, finish
treatment, (3b) if not randomised to second
treatment, process repeated once more. After (3a):
finish treatment
Response defined as: prostate-
specific antigen (PSA) decline of at
least 40% from baseline, objective
regression (of any magnitude) of
any measurable disease,
improvement in any cancer-related
symptom and no new lesions or
new cancer-related symptoms.
Success defined as PSA decline of at
least 80% from baseline, resolution
of all cancer-related symptoms, an
objective tumour regression of at
least 50% from baseline for all
measurable lesions and no new
lesions or cancer-related symptoms
Long-term survival using log
survival time. Efficiency in
diminishing disease burden over 32
weeks using three specific scoring
functions defined as functions of
toxicity and efficacy taking values
in the interval [0,1]
Inverse probability weighting
methods to estimate the mean of
counterfactual outcome for
dynamic treatment regimens and
sequentially randomised trials
No
Rose [30] Two-stage intervention. Stage 1: all received nicotine
patch treatment 2 weeks before quit date.
Responders continue nicotine patch treatment.
Non-responders randomised to (1) control (nicotine
patch), (2) nicotine patch and bupropion or (3)
varenicline alone. Stage 2: for pre-cessation nicotine
patch responders, nonlapsers continue nicotine
patch and for those who lapsed in the first week after
quit date randomised to (1) control (nicotine patch),
(2) nicotine patch and bupropion or (3) varenicline
alone
Ad lib smoking (expired carbon
monoxide levels) decreased by
>50% after 1 week
Continued smoking abstinence at
end of treatment
Logistic regression compared each
rescue treatment against the
control
Yes
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Table 3 Characteristics of included optimal treatment strategy studies (Continued)
First author Intervention Tailoring variable and decision rules
(response unless otherwise stated)
Primary outcome Statistical analysis Analysis
of stages
Kasari [31] Two-stage intervention. Stage 1: sessions of (a)
JASP+EMT or (b) JASP+EMT+SGD. Stage 2: early
responders continue stage 1 treatment. Slow
responders from (1a) randomised to receive
intensified stage 1 treatment or augmented stage 1.
Slow responders from (1b) receive intensified stage 1
treatment
After stage 1, if child demonstrated
25% or greater change on at least
half of the variables (7 out of 14),
then the participant was
considered an early responder
Total spontaneous, communicative
utterances coded from a
standardised Natural Language
Sample
Mixed-effects models compared
outcome between stage 1
treatments. Secondary aim analysis
used a weighted regression to
compare mean outcomes between
the three embedded adaptive
interventions, including an
indicator for stage 1 and 2
treatments
Yes
Kilbourne [36] SMART design for adaptive implementation strategy.
Run-in phase: sites offered REP to implement life
goals for patients with mood disorders. Sites not
initially responding to REP are randomised to receive
additional support from an EF or both EF/IF.
Additionally, sites randomised to EF and still not
responsive will be randomised to continue with EF
alone or to receive EF/IF
<50% patients receiving≥3
evidence-based practice sessions
SF-12 mental-health-related QoL
and PHQ-9 scores
Linear mixed-effects models.
Compare interventions in
non-responding sites beginning
with REP plus EF/IF versus
interventions beginning with REP
plus EF on longitudinal
patient-level change in number of
life-goal sessions received.
Compare whether continuing REP
plus EF versus augmenting with
REP plus EF/IF leads to changes in
outcomes, among sites who are
non-responsive to REP plus EF at
month 12
Yes
Wu [35] Two-stage intervention. Stage 1: patients randomised
to bupropion, paroxetine or placebo. Stage 2:
non-responders assigned second intervention. If
receiving bupropion or paroxetine at stage 1, current
doses increased. If placebo at stage 1, bupropion or
paroxetine
≥50% improvement over initial
SUMD and not meeting DSM-IV
criteria for hypomania or mania
SUMD Q-learning to estimate optimal
regime
Yes
DSM-IV Diagnostic and Statistical Manual of Mental Disorders; EF external facilitator; EMT Enhanced milieu teaching; IF internal facilitator; JASP Joint Attention Symbolic Play Engagement and Regulation; PANSS Positive and Negative
Syndrome Scale; PHQ-9 Patient Health Questionnaire; PSA prostate-specific antigen; QoL quality of life; REP Replicating Effective Programmes; SF-12 12-Item Short Form Health Survey; SGD speech-generating device; SMART Sequential
Multiple Assignment Randomised Trial; SUMD Scale to Assess Unawareness of Mental Disorder
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Fig. 4 SMARTdesignwith second randomisationdependent uponan intermediate outcome response status. SMART Sequential Multiple Assignment
Randomised Trial, R randomise, B/B+, C/C+ and D represent different treatments, with for example, B+ being the more intense version of B
are not able to deal with missing data, (2) they can-
not model the covariance among repeated measures and
(3) a repeated measures ANOVA assumes there is an
exchangeable auto-correlation structure between any two
observations for the same individual [37]. More complex
analysis methods were employed in the SMART stud-
ies that aimed to find the optimal adaptive treatment
strategy.
Trials of proportionate interventions often lead to a
complex hierarchical structure of data, with hierarchi-
cal clustering introduced by both treatment or centre, in
addition to the longitudinal data.
A minority of studies considered the different stages
of the interventions. Some stepped-care studies used an
intention-to-treat analysis to compare the intervention
group to the control group after each step individually
and after the whole intervention period. Only one study
explicitly evaluated the effectiveness of the different com-
ponents as a key objective [17]. Without consideration of
the separate component parts of a proportionate inter-
vention we assume that each component will in itself be
effective. Though this may be true, the effectiveness of
the components might alter as they are incorporated with
one another. By design, the population size of a stepped-
care trial decreases as it passes through the steps. This
makes any comparisons between stages either impossi-
ble or very difficult unless the study has been designed
to account for this. It is possible to evaluate the effec-
tiveness of each stage of a proportionate intervention, as
done by Lamb [17], by randomising patients who are eli-
gible to the active or control treatment, regardless of the
treatment they received at the previous stage. In certain
scenarios, it would be unethical or impossible to withhold
the next stage treatment of a proportionate intervention if
a patient were eligible (for example, if an unstaged version
of the active treatment being tested was used as the con-
trol treatment or if each stage builds upon the previous
stage).
Limitations
Due to resource limitations of this review, it was not pos-
sible to supplement the database by checking reference
lists, conference proceedings or trial registries. Further
work may include a supplementary search. We included
only articles published in English. The studies included
were mainly stepped care, which may suggest that the
search criteria or eligibility criteria were unable to identify
other types of studies that were also trials of proportionate
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interventions. We limited our review to articles published
after 1 January 2010. However, this was to reflect current
practice.
Wider context
There are increasing pressures on health and social care
services, limited resources and increasing health inequali-
ties. Proportionate interventions have a role to play in the
overarching goal of proportionate universalism, both in
reducing health inequalities and providing care to those
in need. If early-stage low-intensity interventions provide
similar outcomes to more intensive interventions, then
costs can be reduced and the health interventions will
be less onerous for some patients and for health profes-
sionals. Increasing the intensity of a treatment does not
necessarily lead to increased effectiveness [38].
Additionally, proportionate interventions fit within the
overarching goals of personalised medicine: to make deci-
sions appropriate to an individual patient, to make deci-
sions that lead to the best outcomes for the patient, and to
formalise clinical decision-making and make it evidence
based. Personalised medicine aims to assign individuals to
interventions based on their individual characteristics and
to target interventions to patients likely to benefit. This
requires evidence on what types of patients will benefit
from different interventions, which is not always avail-
able [39]. In contrast, proportionate interventions can be
self-correcting, with individuals failing to benefit from
lower intensity interventions stepping up to more intense
interventions.
The recommendation from the Marmot review that
interventions follow a proportionate universalism frame-
work has not been supported by the evidence base on how
to evaluate or implement such interventions [2]. The pro-
portionate universalism framework has been discussed in
NICE guidelines [40] and NHS documents [41–43] and
by charities [44] and public health authorities [45]. How-
ever, little has been written in the academic literature on
how to actually implement proportional universalism in
practice or how to assess the effectiveness of these inter-
ventions. This review provides examples of the types of
interventions that fit into the proportionate universalism
framework and the trial designs used to evaluate these at
present.
Implications and recommendations
There have been recent developments in adaptive treat-
ment strategies, and trial designs now exist for optimal
treatment strategies (SMARTs). There are also designs
that evaluate the effectiveness of stepped-care treatments
as a whole. Further research on how to design and anal-
yse trials of proportionate interventions would benefit
from considering when quantifying the effectiveness or
the incremental effectiveness of each stage is necessary
and how this may be implemented. This depends upon
whether the separate stages have been evaluated in a trial
before as well as the interactions between them. Is the
interaction between the different components expected
and of interest?Without this aspect, it may be unclear how
all the components work and how they interact with one
another.
Recent advances in designs of proportionate trials
include just-in-time adaptive interventions. The design
and framework are described in Nahum-Shani et al. [46]
and Klasnja et al. [47]. This design is useful in, for example,
the growing field of educational research for developing
cluster-level adaptive interventions [48], or for compar-
ing adaptive interventions embedded in a SMART [49].
Findings from trials using this framework are forthcom-
ing and could form the basis of, or be included in, future
systematic reviews on mobile health technologies.
Triallists need to account for the impact that mul-
tiple hierarchical levels (often present in proportionate
interventions) have on the analysis. More complex mixed-
effects models accounting for the various correlations may
be necessary, including a consideration of methods for
partially nested trials when clustering is present only in
one arm [50, 51].
Of the 51 studies excluded based on the full texts,
27 were excluded due to a lack of, or the undefined
nature of, the decision stages or rules in the interven-
tion. This lack of clarity was occasionally due to the
decision rule being based on a health professional’s opin-
ion. However, a lack of clarity was also repeatedly due to
limited information in the articles’ explanation of what
the intervention actually entailed. If a trial is to provide
fully useable information and a replicable intervention,
it must give a clear explanation of the decision stages
and rules. The readers can then understand the reason-
ing, and the process can be implemented either in a
different setting or in a further trial. When reporting
trials, it is important to follow both the relevant Con-
solidated Standards of Reporting Trials (CONSORT) [52]
and the Template for Intervention Description and Repli-
cation (TIDieR) [53]. Both state that interventions must
be reported with sufficient detail to allow replication,
including how and when they were administered. This
is particularly pertinent in proportionate interventions,
such as stepped care, since the how and when are often
multifaceted.
Conclusion
The increasing demand on health and social care ser-
vices and medicine has driven the move for propor-
tionate universalism as well as the move towards fairer
and more effective personalised medicine. Appropriate
treatment and service provision according to individual
need is key. Proportionate interventions aim to provide
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individuals with the care they require and reduce the
burden of treatment on an individual whilst reserving
resources for those most in need. The results of this
review have identified various contexts and therapeutic
areas in which trials of proportionate interventions are
being designed and implemented, predominantly in the
treatment of mental health disorders. The term ‘propor-
tionate universalism’ was not used in any of the studies
identified, though analogous terms were used, including
the stepped-care model, adaptive treatment strategy and
dynamic treatment regimen. The two key types of study
designs found in this review included stepped-care stud-
ies and SMART studies. The effectiveness of the different
stages was considered in a minority of studies and often
only as a simple analysis using summary statistics. There
is a need for a more consistent approach and further guid-
ance on the design, analyses and reporting across trials
of proportionate interventions, so that comparisons can
be made.
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